Jenum Synne, Dhanasekaran Sivakumaran, Ritz Christian, Macaden Ragini, Doherty T Mark, Grewal Harleen M S
From the *Department of Clinical Science, University of Bergen, Bergen, Norway; †Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway; ‡Department of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Bergen, Norway; §Department of Nutrition, Exercise and Sports, University of Copenhagen, Copenhagen, Denmark; ¶Division of Infectious Diseases, St. John's Research Institute, Koramangala, Bangalore, India; and ‖GlaxoSmithKline, Vaccines, Wavre, Belgium.
Pediatr Infect Dis J. 2016 Dec;35(12):1336-1338. doi: 10.1097/INF.0000000000001328.
We have explored the added value of interferon-γ (IFNγ)-inducible protein 10 as a read-out of Mycobacterium tuberculosis-specific immunity in young Indian children, where the sensitivity of the IFNγ release assays for tuberculosis is poor. Reduced frequency of indeterminate results and an increased sensitivity for tuberculosis suggest a potential for fewer missed cases with a combined IFNγ/inducible protein 10 read-out in a 4th generation IFNγ release assays.
我们探讨了γ干扰素(IFNγ)诱导蛋白10作为印度幼儿结核分枝杆菌特异性免疫指标的附加价值,在这些幼儿中,IFNγ释放检测对结核病的敏感性较差。不确定结果的频率降低以及对结核病的敏感性增加,表明在第四代IFNγ释放检测中,联合使用IFNγ/诱导蛋白10作为检测指标可能会减少漏诊病例。